Germline BRCA2 mutations predispose to the development of pancreatic cancer. A polymorphic stop codon in the coding region of BRCA2 (K3326X) has been described, and although an initial epidemiological study suggested it was not disease causing, subsequent studies have been inconclusive. To investigate the biological significance of the K3326X polymorphism, we determined its prevalence in patients with sporadic and familial pancreatic cancer. Using a case-control design, we studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with pancreatic cancer, and a disease control group of 135 patients without a personal history of cancer who had undergone cholecystectomy for non-neoplastic disease. The K3326X polymorphism was detected using heteroduplex analysis and DNA sequencing. The BRCA2 K3326X polymorphism was significantly more prevalent in individuals with familial pancreatic cancer: 8/144 (5.6%) vs 3/250 controls (1.2%) (odds ratio, 4.84; 95% CI, 1.27-18.55, Po0.01). One K3326X carrier with familial pancreatic cancer carried an alteration (IVS 16-2A>G) suspected to be deleterious. Excluding this case did not alter the significance of the association (OR: 4.24, Po0.01). In contrast, there was no difference in prevalence among individuals with sporadic pancreatic cancer -7/250 (OR: 2.37, 95% CI: 0.61-9.27). The increased prevalence of the BRCA2 K3326X polymorphism in patients with familial pancreatic cancer suggests that this polymorphism is deleterious and contributes to pancreatic cancer risk.
Germline BRCA2 mutations predispose to the development of pancreatic cancer. A polymorphic stop codon in the coding region of BRCA2 (K3326X) has been described, and although an initial epidemiological study suggested it was not disease causing, subsequent studies have been inconclusive. To investigate the biological significance of the K3326X polymorphism, we determined its prevalence in patients with sporadic and familial pancreatic cancer. Using a case-control design, we studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with pancreatic cancer, and a disease control group of 135 patients without a personal history of cancer who had undergone cholecystectomy for non-neoplastic disease. The K3326X polymorphism was detected using heteroduplex analysis and DNA sequencing. The BRCA2 K3326X polymorphism was significantly more prevalent in individuals with familial pancreatic cancer: 8/144 (5.6%) vs 3/250 controls (1.2%) (odds ratio, 4.84; 95% CI, Po0.01) . One K3326X carrier with familial pancreatic cancer carried an alteration suspected to be deleterious. Excluding this case did not alter the significance of the association (OR: 4.24, Po0.01). In contrast, there was no difference in prevalence among individuals with sporadic pancreatic cancer -7/250 (OR:
Introduction
Pancreatic cancer is the fifth leading cause of cancer death in the United States. Pancreatic ductal adenocarcinomas present typically at an advanced clinical stage so that only 20% of patients are suitable for curative surgical resection (Yeo et al., 1998; DiMagno et al., 1999) . Despite advances in surgical therapy, the overall 5-year survival of pancreatic ductal adenocarcinomas is only 4%, among the worst of the common cancers (Niederhuber et al., 1995) . It is thought that 5-10% of patients with pancreatic cancer have a first-degree relative with pancreatic cancer and that B10-20% of pancreatic cancers arise due to a significant inherited component (Klein et al., 2001; Petersen and Hruban, 2003) . Familial pancreatic cancer is defined as cancers occurring in families in which there are at least two firstdegree relatives with the disease in the absence of other known familial cancer syndromes. The inherited basis of B10-20% of familial pancreatic cancers has been identified and is reflected largely in germline mutations in the BRCA2 gene (Goggins et al., 1996; Ozcelik et al., 1997; Hahn et al., 2003) (The Breast Cancer Linkage Consortium, 1999; Murphy et al., 2002) . Germline mutations in the p16 (Goldstein et al., 1995; Lynch et al., 2000; Vasen et al., 2000; Bartsch et al., 2002) , FANCC (van der Heijden et al., 2003; Rogers et al., 2004) , FANCG (van der Heijden et al., 2003; Rogers et al., 2004) , PRSS1 (Lowenfels et al., 1993 (Lowenfels et al., , 1997 , STK11 (Giardiello et al., 2000; Lim et al., 2004) , and hMLH1 (Yamamoto et al., 2001) genes are infrequent causes of familial pancreatic cancer and are associated with a number of cancer syndromes, including familial multiple mole melanoma (FAMMM), hereditary pancreatitis, hereditary nonpolyposis colon cancer, and Peutz-Jeghers syndrome. In addition, germline BRCA2 mutations are observed in B5% of patients with apparently sporadic pancreatic cancer, that is, patients who do not appear to have an inherited predisposition to pancreatic or breast/ovarian cancer (Goggins et al., 1996; Ozcelik et al., 1997; The Breast Cancer Linkage Consortium, 1999; Figer et al., 2001) . Murphy et al. (2002) recently reported deleterious BRCA2 mutations in up to 17% of familial pancreatic cancers and Hahn et al. (2003) found a prevalence of B12%.
In 1997, while screening for germline BRCA2 mutations in familial breast cancer, Mazoyer et al. (1996) first described a polymorphic stop codon, K3326X, in BRCA2 arising from a 10204 A>T substitution. This premature stop codon results in loss of the final 93 amino acids of the BRCA2 protein. Mazoyer et al. reported an allele frequency of o1% (1/115) in their control population, but did not find an increased prevalence of this polymorphism in patients with breast cancer. The authors of this study concluded that this mutation is a polymorphic nonsense variant, which does not increase cancer risk. Subsequently Krainer et al. (1997) described this mutation in a single case in a cohort of 73 early-onset breast cancers and did not find it in an age-and sex-matched control group of 130 individuals. The K3326X polymorphism has since been identified in patients with a variety of cancers either alone or in combination with obvious pathogenic mutations (Haraldsson et al., 1998; Claes et al., 2003) . Recently, evidence that the K3326X polymorphism may be functionally deleterious came from Howlett and coworkers who, in demonstrating that biallelic inactivation of BRCA2 was a cause of Fanconi's anemia identified a Fanconi anemia individual with the K3326X variant as well as the 3033delAAAC frameshift mutation on exon 11, suggesting that the variant may cause Fanconi's anemia in the compound heterozygote state (Howlett et al., 2002) . In a previous analysis of BRCA2 mutations among 29 patients with familial pancreatic cancer, we identified three patients with the K3326X variant (Murphy et al., 2002) . Since the biological significance of the K3326X variant remains uncertain, we performed a genetic epidemiological study to determine the role of the K3326X variant in the development of sporadic and familial pancreatic cancer.
Results
The K3326X polymorphism was present in eight of 144 individuals (5.5%) with familial pancreatic cancer (five female) compared to only 1.2% of controls (OR: 4.84, 95% CI: 1.27-18.55). Among the controls, K3326X was present in one of 135 (0.75%) controls with chronic cholecystitis and in two of 115 (1.75%) of the spousal controls. In contrast, there was no significant increase in the prevalence of the K3326X polymorphism among patients with sporadic pancreatic cancer: seven out of 250 patients with sporadic pancreatic cancer carried the K3326X polymorphism (OR: 2.37, 95% CI: 0.61-9.27). While our sample size was adequately powered to detect B5-fold differences observed between the familial pancreatic cancer group and controls, our sample size was underpowered to detect more modest differences in the prevalence of the K3326X polymorphism such as the two-to threefold higher prevalence in those with sporadic pancreatic cancer compared to controls. All of the K3326X carriers were heterozygous for the polymorphism. The familial pancreatic cancer individuals carrying the K3326X variant underwent analysis of the entire BRCA2 coding sequence for synchronous disease causing mutations. Four K3326X variant carriers also harbored the IVS 24-16T>C polymorphism, previously described as associated with K3326X. This intronic polymorphism is not thought to be deleterious (Claes et al., 2003) . One of these four patients also had an IVS 16-2A>G mutation, which is suspected to be deleterious. Excluding this patient, 7/143 familial pancreatic cancer patients carried the K3326X variant carriers without a known BRCA2 deleterious alteration (OR compared to controls: 4.24, w 2 ¼ 5.3, Po0.05). The only other alteration found in one K3326X carrier was a T598A polymorphism (M192T), not known to be deleterious. None of the eight familial cases harboring the K3326X variant carried the 6503-6504delTT mutations, which has previously been found in linkage disequilibrium with K3326X in some patients (Mazoyer et al., 1996; Haraldsson et al., 1998) . The mean age at diagnosis of patients with pancreatic cancer that harbored the K3326X polymorphism was 57.8 years. A family history of breast cancer was present in only two of the eight kindreds of those who tested positive for the K3326X variant, and in these families only one member in each family had breast cancer: a maternal aunt in one family and a sister in another family. We could not identify segregation of the mutant allele in families due to unavailability of DNA from family members of K3326X carriers.
Discussion
Germline BRCA2 mutations are the most common known cause of inherited susceptibility to pancreatic cancer. In this study, we find evidence that the BRCA2 K3326X polymorphism occurs more frequently in an unselected group of patients with familial pancreatic cancer than in controls. The prevalence of K3326X in our control population (1.2%) is consistent with that observed in previous studies (Mazoyer et al., 1996) . Prior genetic epidemiological studies of the K3326X polymorphism have identified several polymorphisms and deleterious mutations that sometimes occur with it in linkage disequilibrium. As in our study, many K3326X carriers also carried the IVS 24-16T>C polymorphism (Claes et al., 2003) . Only one of the K3326X carriers in our familial pancreatic cancer group harbored a suspected deleterious mutation. Although our familial pancreatic cancer study population of patients is large for studies of this disease (144 patients), it is not large for genetic epidemiological studies comparing polymorphism prevalence in different populations. Thus, it is important that our findings are verified in other populations with BRCA2-related cancers such as those with breast and ovarian cancer. Our findings in conjunction with evidence that a patient with Fanconi anemia was attributed to biallelic mutation of BRCA2 with one alteration being K3326X (Howlett et al., 2002) suggest a pathogenic role for this mutation. An alternative explanation is that the K3326X polymorphism may occur in linkage disequilibrium with other disease susceptibility alleles outside of the BRCA2 coding sequence. However, none of the genes adjacent to the BRCA2 locus are suspected to be tumor suppressor genes. The K3326X polymorphism results in loss of the last 91 amino acids of BRCA2. The C-terminus of BRCA2 is thought to be functionally important. For example, BRCA2 protein from a patient with Fanconi anemia with C-terminal deletion of BRCA2 (3226-3418) was unable to colocalize with FANCD2 (Wang et al., 2004) . Similarly, mouse cells with truncated BRCA2 lacking the last 188 amino acids are hypersensitive to radiation (Morimatsu et al., 1998) . These data support the notion that the K3326X polymorphism is deleterious.
In conclusion, our genetic epidemiological evidence suggests that the K3326X polymorphism contributes to the risk of developing familial pancreatic cancer. Further studies are needed to determine the biological significance of the K3326X polymorphism.
Materials and methods

Subjects
The study population consisted of an unselected population of 144 patients with familial pancreatic adenocarcinoma (mean age of 66.7712.3 years, males 50.3%), 250 patients with sporadic pancreatic adenocarcinoma (mean age, 64 years), and 250 controls including 135 patients who had previously undergone cholecystectomy for cholecystitis and 115 healthy spouses of patients with familial pancreatic cancer. Germline BRCA2 analysis had been performed on 29 of the patients with familial pancreatic cancer previously (Murphy et al., 2002) . The cholecystectomy controls were frequency matched to cases for sex, self-reported ethnicity, and age to within 5 years to the sporadic pancreatic cancer population, and had undergone cholecystectomy for the treatment of benign gall-bladder disease at the Johns Hopkins Hospital between 1986 and 2000. The clinical histories of cholecystectomy patients were reviewed by chart review and those reporting a personal prior history of cancer were excluded from selection, as were those whose cholecystectomy was incident to a liver transplant. All patients with sporadic pancreatic cancer had undergone pancreaticoduodenectomy for their disease at The Johns Hopkins hospital between 1993 and 2000. The 144 patients with familial pancreatic cancer were chosen from the National Familial Pancreatic Tumor Registry (NFPTR) (http://www.path.jhu.edu/pancreas_NFPTR) based on availability of a blood sample from an affected individual with pancreatic cancer. The NFPTR was established in 1994 to provide a resource for studying familial pancreatic cancer, and as of April 1, 2004, 1283 kindreds have enrolled in the NFPTR. Kindreds are eligible to enroll if at least one family member has been diagnosed with pancreatic cancer. Kindreds are recruited through the World-Wide Web (http://pathology2. jhu.edu/pancreas), by direct referral and through contact with patients treated for pancreatic cancer at the Johns Hopkins Medical Institutions.
Tissue specimens
DNA was isolated from macroscopically normal duodenal mucosa of patients undergoing pancreaticoduodenectomy for sporadic pancreatic adenocarcinoma, from peripheral blood mononuclear cells of patients with familial pancreatic cancer, and from the gallbladders of patients with cholecystitis. The duodenal tissues obtained from patients with sporadic pancreatic cancer was usually frozen tissues that had been stored at À801C since the time of surgery. When frozen tissue was unavailable, 10 mM sections of formalin-fixed paraffinembedded tissue was used.
DNA extraction
DNA from peripheral blood mononuclear cells and from B1 mg of frozen tissue was extracted using a Dneasy Tissue kit (Qiagen, Valencia, CA, USA). DNA was extracted from paraffin-embedded formalin-fixed tissue sections using TK buffer as described previously (Matsubayashi et al., 2003) .
BRCA2 K3326X polymorphism detection
The BRCA2 K3326X polymorphism was determined by first analysing PCR products using temperature gradient capillary electrophoresis (TGCE) for heteroduplex formation followed by DNA sequencing of PCR products with heteroduplex alterations. A 226 bp PCR product spanning the A10204T polymorphism in exon 27 was amplified using forward primer 5 0 -GCT GCA CAG AAG GCA TTT C-3 0 and reverse primer 5 0 -GAT TCA CTG ACA GAT ATA AAT TG-3 0 . In all, 40 cycles of PCR were performed for DNA isolated from frozen tissue and peripheral blood cells and 45 cycles for DNA isolated from paraffin-embedded tissue. To form heteroduplexes, PCR products were diluted 1 : 5 in 1 Â Amplitaq PCR buffer (Applied Biosystems) and 2.5 mM MgCl 2 , and samples were thermocycled using the following program: 951C for 3 min, followed by ramping down from 95 to 801C by 31C/min, 80 to 501C for 11C/min, followed by 501C for 20 min, ramping down from 50 to 451C by 11C/min, 45 to 251C by 21C/min then holding at 41C. TGCE was performed using an SCE 9610 (SpectruMedix Corporation, State College, PA, USA), each amplicon being scanned at three different overlapping temperature gradients (injections), 35-45, 50-60, and 55-651C . DNA samples known to harbor the K3326X variant were used as positive controls. Heteroduplexes were identified with the Revelation mutational discovery software (Version 2.4, SpectruMedix Corporation, State College, PA, USA) (see Figure 1 ). For cycle sequencing, PCR products were purified using the Qiaquick PCR clean-up kit and sequenced with an ABI 3700 automated capillary sequencer. Sequences were analysed using the forward sequencing primer 5 0 -ACA ATT TAT ATC TGT CAG TGA ATC-3 0 .
Analysis of K3326X carriers for BRCA2 mutations
The eight cases positive for the K3326X variant were screened for synchronous BRCA2 mutations by dHLPC analysis (Transgenomics Inc., Carpentaria, CA, USA) of PCR products using PCR primers flanking the 27 exons of BRCA2 (primers available on request). PCR products were heteroduplexed, loaded onto a Transgenomic WAVE dHPLC system, and analysed using product-specific melting temperatures. When altered peaks were identified on the dHPLC analysis, the original genomic DNA was reamplified by PCR and sequenced in both directions to confirm presence of the variant (Table 1) .
Statistics
Our preliminary data indicated a possible prevalence of the K3326X polymorphism in cases with familial pancreatic cancer of 10%. We estimated that the sample size needed to have an 80% power to detect a significant difference between the familial pancreatic cancer group and controls having a prevalence of 1% was nine cases and 150 controls (assuming Po0.05, and two-sided tests of significance). Our sample size had an 80% power to detect a sixfold increased prevalence of the K3326X polymorphism in the familial pancreatic cancer group. Our sample size had 75% power to detect a fivefold difference in the increased prevalence of the polymorphism in the sporadic pancreatic cancer group. The prevalence of the K3326X polymorphism was compared in different populations using w 2 analysis. Two-sided tests of significance were used. 
